1. known history of severe chronic pulmonary disease (e.g., preinfection requirement for home oxygen therapy or presence of chronic hypercapnia (paco2\< 50 mm hg); mild -moderate disease is still eligible in the absence of chronic hypercapnia or need for chronic oxygen therapy) 2. in the opinion of the pi, unlikely to survive for \>48 hours from time of enrollment 3. enrollment in another trial of anti-inflammatory therapies for covid-19. 4. known allergy to furosemide or sulfonamide agents

1. known history of severe chronic pulmonary disease (e.g., preinfection requirement for home oxygen therapy or presence of chronic hypercapnia (paco2\< 50 mm hg); mild -moderate disease is still eligible in the absence of chronic hypercapnia or need for chronic oxygen therapy) 2. in the opinion of the pi, unlikely to survive for \>48 hours from time of enrollment 3. enrollment in another trial of anti-inflammatory therapies for covid-19. 4. known allergy to furosemide or sulfonamide agents

known history of severe chronic pulmonary disease (e.g., preinfection requirement for home oxygen therapy or presence of chronic hypercapnia (paco2< 50 mm hg); mild -moderate disease is still eligible in the absence of chronic hypercapnia or need for chronic oxygen therapy) in the opinion of the pi, unlikely to survive for >48 hours from time of enrollment enrollment in another trial of anti-inflammatory therapies for covid-19. known allergy to furosemide or sulfonamide agents

known history of severe chronic pulmonary disease (e.g., preinfection requirement for home oxygen therapy or presence of chronic hypercapnia (paco2< 50 mm hg); mild -moderate disease is still eligible in the absence of chronic hypercapnia or need for chronic oxygen therapy) in the opinion of the pi, unlikely to survive for >48 hours from time of enrollment enrollment in another trial of anti-inflammatory therapies for covid-19. known allergy to furosemide or sulfonamide agents

1. known history of severe chronic pulmonary disease (e.g., preinfection requirement for home oxygen therapy or presence of chronic hypercapnia (paco2< 50 mm hg); mild -moderate disease is still eligible in the absence of chronic hypercapnia or need for chronic oxygen therapy) 2. in the opinion of the pi, unlikely to survive for >48 hours from time of enrollment 3. enrollment in another trial of anti-inflammatory therapies for covid-19. 4. known allergy to furosemide or sulfonamide agents

1. known history of severe chronic pulmonary disease (e.g., preinfection requirement for home oxygen therapy or presence of chronic hypercapnia (paco2< 50 mm hg); mild -moderate disease is still eligible in the absence of chronic hypercapnia or need for chronic oxygen therapy) 2. in the opinion of the pi, unlikely to survive for >48 hours from time of enrollment 3. enrollment in another trial of anti-inflammatory therapies for covid-19. 4. known allergy to furosemide or sulfonamide agents

1. known history of severe chronic pulmonary disease (e.g., preinfection requirement for home oxygen therapy or presence of chronic hypercapnia (paco2< 50 mm hg); mild -moderate disease is still eligible in the absence of chronic hypercapnia or need for chronic oxygen therapy) 2. in the opinion of the pi, unlikely to survive for >48 hours from time of enrollment 3. treatment with anti-il 6, anti-il-6r antagonists, or with janus kinase inhibitors (jaki) in the past 30 days or plans to receive during the study period 4. known allergy to furosemide or sulfonamide agents

1. known history of severe chronic pulmonary disease (e.g., preinfection requirement for home oxygen therapy or presence of chronic hypercapnia (paco2< 50 mm hg); mild -moderate disease is still eligible in the absence of chronic hypercapnia or need for chronic oxygen therapy) 2. in the opinion of the pi, unlikely to survive for >48 hours from time of enrollment 3. treatment with anti-il 6, anti-il-6r antagonists, or with janus kinase inhibitors (jaki) in the past 30 days or plans to receive during the study period 4. known allergy to furosemide or sulfonamide agents